Li et al. found that an isocorydine derivative (d-ICD) negatively regulates the proliferation of CD133(+) cancer stem cells (CSCs) by targeting IGF2BP3, thereby inhibiting sorafenib resistance in HCC cells [61]. Here, IGF2BP3 is linked to cancer.